ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio

In a heated race with some of pharma’s biggest players, Roche’s Genentech is looking to drive a lead bispecific antibody program through the clinic against stubborn blood cancers. As the field watches closely, Roche is now trotting out data it thinks could earn its drug a first shot at the market.